We are monitoring the impact of COVID-19 on Europe Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1114
Share on
Share on

Europe Antibodies Market Research Report – Segmented By Product Type, Indication, End User, Application & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1114
Pages: 145

Europe Antibodies Market Size (2021 to 2026)

The size of the Antibodies Market in Europe is worth USD 35.41 Billion in 2021. It is estimated to reach USD 60.77 Billion by the end of 2026, with a growing potential of 11.41 % during the forecast period.

An efficient resource for the therapy of complex disorders with minor side effects has enhanced the growth of antibodies-based therapeutics against chemical drugs.

Innovative products primarily drive the antibody market in the European region, increasing the adoption rate of therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies.

In terms of research, the antibody market in the European region is rapidly expanding, and there is continuous innovation and advancements in the sector. The constant invention of newer, more inventive items is proven to boost market demand. In addition, extremely cost-conscious markets are now adjusting to therapeutic antibodies are expected to accelerate the growth rate of the European antibodies market. Furthermore, patients benefit from the increasing network of clinics in established and emerging economies, which increases accessibility and convenience. Furthermore, clinician knowledge of new treatments and the availability of competent people is expected to boost the market’s growth rate during the forecast period.

Along with illness prevalence, the market size will gain from increased treatment spending abilities on modern medicines. Moreover, continuing technology improvements, improved accessibility, and growing disposable income are expected to influence the industry's growth. The fertile environment for the new therapeutic antibodies, government policies are further helping the industry to flourish. The companies adapt to the changing market and orient their business plan and policies to help increase the antibodies sector.

However, the high cost of treatment and side effects associated with antibody treatment are the restraints affecting the growth of the European antibodies market.  Certain treatments, such as monoclonal antibody therapy, are costly and difficult for patients to afford. Also, the stringent regulatory system and government policies are very time-consuming and make the product's entrance more complex, resulting in fewer competitors entering the market, which limits market expansion. Furthermore, the therapy's safety and effectiveness are questioned. As a result, it is seen to be limiting the sector's growth. Fever, chills, nausea, vomiting, and other adverse effects are common with an antibody treatment. As a result, patients tend to mistrust the therapy's efficacy, limiting the sector's expansion. Also, the presence of alternative therapies and treatments in the market affects market growth.

This research report on the European antibodies market has been segmented and sub-segmented into the following categories:

By Product Type:

  • Monoclonal Antibodies
    • Murine
    • Chimeric
    • Humanized
    • Human
  • Polyclonal Antibodies
    • Type I
    • Type II
    • Type III
    • Type IV
    • Type V
    • Type VI
    • Type VII
    • Type VIII
  • Anti-body drug complexes
    • Immunogen Technology
    • Seattle Genetics Technology
    • Immunomedics Technology

By Indication:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End User:

  • Hospitals/Clinics
  • Research institute
  • Diagnostics laboratories

By Application:

  • Medical
  • Experimental
  • Western blot
  • ELISA
  • Radioimmune Assays
  • Immunofluorescence
  • Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European region is expected to be the second-largest regional market in the global antibodies market. For the manufacture of monoclonal antibodies, European laboratories have partnered with academic institutes. As a result, Europe has a well-developed laboratory infrastructure expected to drive market demand to a high level. Furthermore, the market's growth pace is being accelerated by the rising prevalence of different health conditions. 

The researchers utilize this monoclonal antibody as a study or diagnostic tool, employing several methodological strategies for improving antibody manufacturing, such as recombinant technology. 

In 2020, Germany's revenue share in European industry was above 18 percent. Due to the growing frequency of infectious disorders such as COVID-19, the contagious disease category may expand at a 14.1 percent CAGR from 2021 to 2027, driving product research and development.

Along with illness prevalence, the market size will gain from increased treatment spending abilities on modern medicines. Moreover, the industry's development in this region will be influenced by ongoing technology improvements and improved accessibility. In addition, these industries and market players undertake growing disposable income with various strategic initiatives to extend their regional presence and product reach.

KEY MARKET PLAYERS:

A few noteworthy companies in the European antibodies market analyzed in this report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Merck KGaA (Germany)                        

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 bioMerieux (France)               

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Qiagen N.V. (Netherlands)                

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  2. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Polyclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Antibody-Drug complexes Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  6. Europe Cancer Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Auto immune diseases Market, By Region, From 2021 to 2026 (USD Million)
  8. Europe infectious diseases Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Cardiovascular diseases Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe CNS disorders Market, By Region, From 2021 to 2026 (USD Million)
  11. Europe Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  12. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Research institute Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Diagnostics laboratories Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  16. Europe Medical Market, By Region, From 2021 to 2026 (USD Million)
  17. Europe Experimental Market, By Region, From 2021 to 2026 (USD Million)
  18. U.K. Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  19. U.K. Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  20. U.K. Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  21. U.K. Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  22. Germany Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  23. Germany Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  24. Germany Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  25. Germany Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  26. France Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  27. France Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  28. France Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  29. France Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  30. Italy Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  31. Italy Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  32. Italy Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  33. Italy Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  34. Spain Antibodies Market, By Product type, From 2021 to 2026 (USD Million)
  35. Spain Antibodies Market, By Indication, From 2021 to 2026 (USD Million)
  36. Spain Antibodies Market, By End users, From 2021 to 2026 (USD Million)
  37. Spain Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  38. Europe Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  39. Europe Murine Market, By Region, From 2021 to 2026 (USD Million)
  40. Europe Chimeric Market, By Region, From 2021 to 2026 (USD Million)
  41. Europe Humanized Market, By Region, From 2021 to 2026 (USD Million)
  42. Europe Human Market, By Region, From 2021 to 2026 (USD Million)
  43. U.K. Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  44. Germany Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  45. France Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  46. Italy Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  47. Spain Antibodies Market, By Monoclonal Antibodies, From 2021 to 2026 (USD Million)
  48. Europe Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  49. Europe Type I Market, By Region, From 2021 to 2026 (USD Million)
  50. Europe Type II Market, By Region, From 2021 to 2026 (USD Million)
  51. Europe Type III Market, By Region, From 2021 to 2026 (USD Million)
  52. Europe Type IV Market, By Region, From 2021 to 2026 (USD Million)
  53. Europe Type V Market, By Region, From 2021 to 2026 (USD Million)
  54. Europe Type VI Market, By Region, From 2021 to 2026 (USD Million)
  55. Europe Type VII Market, By Region, From 2021 to 2026 (USD Million)
  56. Europe Type VIII Market, By Region, From 2021 to 2026 (USD Million)
  57. U.K. Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  58. Germany Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  59. France Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  60. Italy Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  61. Spain Antibodies Market, By Polyclonal Antibodies, From 2021 to 2026 (USD Million)
  62. Europe Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  63. Europe Immunogen Technology Market, By Region, From 2021 to 2026 (USD Million)
  64. Europe Seattle Genetics Technology Market, By Region, From 2021 to 2026 (USD Million)
  65. Europe Immunomedics technology Market, By Region, From 2021 to 2026 (USD Million)
  66. U.K. Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  67. Germany Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  68. France Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  69. Italy Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  70. Spain Antibodies Market, By Antibody-Drug Complexes, From 2021 to 2026 (USD Million)
  71. Europe Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)
  72. Europe Western Blot Market, By Region, From 2021 to 2026 (USD Million)
  73. Europe ELISA Market, By Region, From 2021 to 2026 (USD Million)
  74. Europe Radioimmune Assays Market, By Region, From 2021 to 2026 (USD Million)
  75. Europe immunoflourscence Market, By Region, From 2021 to 2026 (USD Million)
  76. U.K. Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)
  77. Germany Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)
  78. France Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)
  79. Italy Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)
  80. Spain Antibodies Market, By Experimental, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample